NCT06691828View on ClinicalTrials.gov

Absolute Bioavailability, Absorption, Metabolism, Excretion, and Mass Balance Study of [14C] NX-5948

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 28, 2024

Study Completion Date

December 5, 2024

Conditions
Healthy Volunteer
Interventions
DRUG

NX-5948

NX-5948 will be given once by IV and then given once by mouth.

Trial Locations (1)

68502

Celerion, Lincoln

Sponsors
All Listed Sponsors
lead

Nurix Therapeutics, Inc.

INDUSTRY